| Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study M Hutchings, R Mous, MR Clausen, P Johnson, KM Linton, ... The Lancet 398 (10306), 1157-1169, 2021 | 215 | 2021 |
| A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation M Lala, TR Li, DP de Alwis, V Sinha, K Mayawala, N Yamamoto, LL Siu, ... European Journal of Cancer 131, 68-75, 2020 | 130 | 2020 |
| FcRn expression in wildtype mice, transgenic mice, and in human tissues T Li, JP Balthasar Biomolecules 8 (4), 115, 2018 | 28 | 2018 |
| Application of physiologically based pharmacokinetic modeling to predict the effects of FcRn inhibitors in mice, rats, and monkeys T Li, JP Balthasar Journal of Pharmaceutical Sciences 108 (1), 701-713, 2019 | 21 | 2019 |
| Pivotal dose of pembrolizumab: a dose‐finding strategy for Immuno‐oncology TR Li, M Chatterjee, M Lala, AK Abraham, T Freshwater, L Jain, V Sinha, ... Clinical Pharmacology & Therapeutics 110 (1), 200-209, 2021 | 19 | 2021 |
| “Catch-and-Release” anti-carcinoembryonic antigen monoclonal antibody leads to greater plasma and tumor exposure in a mouse model of colorectal cancer FA Engler, JR Polli, T Li, B An, M Otteneder, J Qu, JP Balthasar Journal of Pharmacology and Experimental Therapeutics 366 (1), 205-219, 2018 | 15 | 2018 |
| Subcutaneous epcoritamab in patients with relapsed/refractory chronic lymphocytic leukemia: preliminary results from the Epcore CLL-1 trial AP Kater, JH Christensen, HH Bentzen, CU Niemann, M Hutchings, ... Blood 138, 2627, 2021 | 14 | 2021 |
| Development and evaluation of a physiologically based pharmacokinetic model for predicting the effects of anti-FcRn therapy on the disposition of endogenous IgG in humans T Li, JP Balthasar Journal of Pharmaceutical Sciences 108 (1), 714-724, 2019 | 14 | 2019 |
| Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas T Li, IH Hiemstra, C Chiu, RS Oliveri, B Elliott, D DeMarco, T Salcedo, ... Clinical Pharmacology & Therapeutics 112 (5), 1108-1119, 2022 | 7 | 2022 |
| Novel semi-mechanistic model leveraging preclinical and clinical data to inform the recommended phase 2 dose (RP2D) selection for epcoritamab (DuoBody CD3xCD20) T Li, IH Hiemstra, C Chiu, RS Oliveri, D DeMarco, TW Salcedo, FL Egerod, ... Blood 136, 35-36, 2020 | 6 | 2020 |
| Investigation of the influence of protein-losing enteropathy on monoclonal antibody pharmacokinetics in mice Y Yang, TR Li, JP Balthasar The AAPS journal 19, 1791-1803, 2017 | 4 | 2017 |
| Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1 JM Vose, T Feldman, MED Chamuleau, WS Kim, P Lugtenburg, TM Kim, ... Blood 142, 1729, 2023 | 1 | 2023 |
| Evaluation of epcoritamab and rituximab combination in preclinical models of B-cell non-Hodgkin's lymphoma (NHL) PK Epling-Burnette, DB Dandamudi, IM Konieczna, KM Calabrese, ... Blood 140 (Supplement 1), 9283-9285, 2022 | 1 | 2022 |
| " Catch-and-Release" anti-CEA mAb leads to greater plasma and tumor exposure in a mouse model of colorectal cancer FA Engler, JR Polli, TR Li, B An, MB Otteneder, J Qu, JP Balthasar Journal of Pharmacology and Experimental Therapeutics, 2018 | 1 | 2018 |
| Identification of Optimal Dosing Regimen for Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma T Li, L Gibiansky, A Parikh, CW Chiu, M Sacchi, H Feng, T Ahmadi, ... Blood 142, 3135, 2023 | | 2023 |
| Population Pharmacokinetics of Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma T Li, L Gibiansky, A Parikh, M van der Linden, K Sanghavi, M Putnins, ... Blood 142, 4481, 2023 | | 2023 |
| Bispecific antibodies against cd3 and cd20 T Ahmadi, M Gupta, TR Li, R Oliveri, D Demarco, I Hiemstra, C Chiu, ... US Patent App. 17/923,317, 2023 | | 2023 |
| Utilizing quantitative systems pharmacology (QSP) model to understand cytokine release syndrome (CRS) following administration of epcoritamab in DLBCL patients N Afzal, T Li, C Chiu, M Sacchi, M Gupta, S Xu, CJ Thalhauser Cancer Research 83 (7_Supplement), 846-846, 2023 | | 2023 |
| Simplifying selection and optimization of step-up dosing of subcutaneous Epcoritamab to mitigate CRS risk using repeated time-to-event modeling T Li, D Polhamus, C Thalhauser, A Parikh, M Gupta, M Sacchi, S Xu Cancer Research 83 (7_Supplement), 2798-2798, 2023 | | 2023 |
| ANTI-TIGIT ANTIBODY DOSAGE REGIMEN FOR THE TREATMENT OF CANCER CAI Mingmei, EK Chartash, JA HEALY, L Mallika, TR LI, K Mayawala, ... | | 2022 |
